Ibuprofen,
does it really help with Two-hour pain relief during an acute migraine attack?
research showsIbuprofen is rated B because it directly relieves acute migraine pain at two hours. The pivotal trial randomized and analyzed 660 participants, and both co-primary endpoints, two-hour headache relief and pain-intensity difference, succeeded. Across nine trials and 4,373 participants, Cochrane found two-hour pain freedom with 400 mg in 26% versus 12% and headache relief in 57% versus 25%. Benefit is replicated, but complete pain freedom remains limited.
ads claimPain relief must not be advertised as complete two-hour freedom or a recurrence-free day for every attack.
Useful facts when choosing a product
- Earlier use during an attack tends to work better.
- Nonprescription label doses and daily limits should be followed.
- Frequent use can contribute to medication-overuse headache.
What the research actually shows
The 2001 double-blind trial assigned and analyzed 660 participants: 216 to 200 mg, 223 to 400 mg, and 221 to placebo. Both co-primary endpoints succeeded. Cochrane synthesized nine trials with 4,373 participants and reported NNT 7.2 for pain freedom and 3.2 for headache relief with 400 mg.
Why this is classified as B (68)
Across nine trials and 4,373 participants, the NNT was 7.2 for two-hour pain freedom and 3.2 for headache relief. Codispoti 2001 was manufacturer-led by McNeil Consumer Healthcare, and academic-led trials in the Cochrane review did not report funding, leaving zero randomized trials with confirmed nonmanufacturer funding. The evidence nevertheless spans several separate sponsors and academic investigator groups rather than one manufacturer development program, supporting B with 68 points. This differs from verdict 1682, which is C with 58 points, because its gabapentin evidence was concentrated in one manufacturer program.
Counterpoint. It is reasonable for many uncomplicated attacks, while repeated failure or frequent migraine warrants assessment for migraine-specific acute or preventive therapy.
Rejudgment record. Cross-check applied — Patient-reported pain is a direct treatment target, and evidence across nine trials and 4,373 participants yielded NNT 7.2 for two-hour pain freedom and 3.2 for headache relief. Codispoti 2001 was manufacturer-led by McNeil Consumer Healthcare, while academic-led trials in the Cochrane review did not report funding, leaving zero randomized trials with confirmed nonmanufacturer funding. The evidence nevertheless spans several separate sponsors and academic investigator groups rather than one manufacturer development program, supporting B. This differs from verdict 1682, which is C with 58 points, because its gabapentin evidence was concentrated in one manufacturer program
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Two-hour headache relief | B | A major trial and meta-analysis were repeatedly positive. |
| Complete pain freedom at two hours | B | It exceeds placebo, but the absolute rate is 26%. |
| Sustained pain relief over 24 hours | B | A replicated signal exists, but benefit is more limited than two-hour relief. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Codispoti JR et al. 2001 | Randomized double-blind placebo-controlled trial | 221 | Manufacturer-led product-development study by McNeil Consumer Healthcare | Co-primary two-hour headache relief and pain-intensity difference | Both co-primary endpoints succeeded (P≤0.006 and P≤0.001). | Pivotal direct efficacy evidence |
| Rabbie R et al. 2013 Cochrane review | Systematic review and meta-analysis of randomized trials | 4,373 | Review supported by noncommercial Pain Research Funds, NHS Cochrane, and NIHR; included academic-led trials did not report funding, leaving zero randomized trials with confirmed nonmanufacturer funding | Two-hour pain freedom and headache relief | With 400 mg, pain freedom was 26% versus 12%, NNT 7.2; relief was 57% versus 25%, NNT 3.2. | Replication and absolute-effect assessment |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Ibuprofen x two-hour acute migraine pain relief — Evidence Grade B·68. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/ibuprofen-acute-migraine-two-hour-pain-relief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.